Your browser doesn't support javascript.
loading
Antibiotics for Preventing Recurrent Urinary Tract Infection: Systematic Review and Meta-analysis.
Jent, Philipp; Berger, Julia; Kuhn, Annette; Trautner, Barbara W; Atkinson, Andrew; Marschall, Jonas.
Afiliação
  • Jent P; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Berger J; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Kuhn A; Department of Gynecology, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Trautner BW; Center for Innovations in Quality, Effectiveness, and Safety (IQuESt), Michael E. DeBakey Veterans Affairs Medical Center and Section of Health Services Research, Baylor College of Medicine, Houston, Texas, USA.
  • Atkinson A; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Marschall J; Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Open Forum Infect Dis ; 9(7): ofac327, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35899289
Recurrent urinary tract infections are a common health problem. The only comprehensive synthesis on antibiotic prophylaxis in the last 15 years has been a guideline-embedded meta-analysis. We conducted a systematic review and meta-analysis of randomized controlled trials published up to October 13, 2020, evaluating patients age ≥12 years with either ≥2 episodes of lower urinary tract infection (UTI) within 6 months or ≥3 in the past year. Placebo or antibiotics were allowed as comparators. Study quality was low. In the 11 placebo-controlled trials, the risk for developing UTI was 85% lower with prophylaxis in comparison with placebo (risk ratio [RR], 0.15; 95% CI, 0.08-0.29). In the 9 head-to-head trials, the efficacy of the antibiotic agents appeared similar: The pooled RR indicated no difference between nitrofurantoin and comparators (RR, 1.01; 95% CI, 0.74-1.37), nor trimethoprim (+/- sulfamethoxazole; RR, 1.34; 95% CI, 0.89-2.03) or norfloxacin and comparators (RR, 1.17; 95% CI, 0.43-1.70). Studies comparing intermittent (postcoital) with continuous strategies revealed intermittent application to be equally effective.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Systematic_reviews Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Systematic_reviews Idioma: En Revista: Open Forum Infect Dis Ano de publicação: 2022 Tipo de documento: Article